Do analysts prefer HCAT or MDRX?

Health Catalyst presently has a consensus target price of $2.93, indicating a potential upside of 67.53%. Given Health Catalyst's stronger consensus rating and higher possible upside, equities analysts plainly believe Health Catalyst is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health Catalyst 1 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.23 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, HCAT or MDRX?

Veradigm has higher revenue and earnings than Health Catalyst. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Catalyst $311.14M 0.42 -$177.97M -$3.68 N/A Veradigm $1.53B 0.40 N/A N/A N/A

Does the media prefer HCAT or SOPH?

In the previous week, SOPHiA GENETICS had 16 more articles in the media than Health Catalyst. MarketBeat recorded 30 mentions for SOPHiA GENETICS and 14 mentions for Health Catalyst. SOPHiA GENETICS's average media sentiment score of 0.07 beat Health Catalyst's score of -0.08 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral SOPHiA GENETICS 9 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor WEAV or HCAT?

In the previous week, Health Catalyst had 11 more articles in the media than Weave Communications. MarketBeat recorded 14 mentions for Health Catalyst and 3 mentions for Weave Communications. Weave Communications' average media sentiment score of 0.57 beat Health Catalyst's score of -0.08 indicating that Weave Communications is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Weave Communications 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Health Catalyst 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CTEV or HCAT?

In the previous week, Claritev had 10 more articles in the media than Health Catalyst. MarketBeat recorded 24 mentions for Claritev and 14 mentions for Health Catalyst. Claritev's average media sentiment score of 0.41 beat Health Catalyst's score of -0.08 indicating that Claritev is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Claritev 4 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Health Catalyst 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer HCAT or NRC?

In the previous week, Health Catalyst had 12 more articles in the media than National Research. MarketBeat recorded 14 mentions for Health Catalyst and 2 mentions for National Research. National Research's average media sentiment score of 1.75 beat Health Catalyst's score of -0.08 indicating that National Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral National Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Health Catalyst (HCAT) Competitors

$1.75 -0.04 (-2.23%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.57%)

As of 05:26 AM Eastern

Compare

HCAT vs. MDRX, SOPH, WEAV, CTEV, and NRC

Should you buy Health Catalyst stock or one of its competitors? Health Catalyst's main competitors and comparable companies include Veradigm (MDRX), SOPHiA GENETICS (SOPH), Weave Communications (WEAV), Claritev (CTEV), and National Research (NRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Health Catalyst compare to Veradigm?

Health Catalyst (NASDAQ:HCAT) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

85.0% of Health Catalyst shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Veradigm has a net margin of 0.00% compared to Health Catalyst's net margin of -90.61%. Veradigm's return on equity of 0.00% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.57%	-0.75%
Veradigm	N/A	N/A	N/A

Veradigm has higher revenue and earnings than Health Catalyst.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
Veradigm	$1.53B	0.40	N/A	N/A	N/A

In the previous week, Health Catalyst had 14 more articles in the media than Veradigm. MarketBeat recorded 14 mentions for Health Catalyst and 0 mentions for Veradigm. Veradigm's average media sentiment score of 0.00 beat Health Catalyst's score of -0.08 indicating that Veradigm is being referred to more favorably in the news media.

Company	Overall Sentiment
Health Catalyst	Neutral
Veradigm	Neutral

Health Catalyst presently has a consensus target price of $2.93, indicating a potential upside of 67.53%. Given Health Catalyst's stronger consensus rating and higher possible upside, equities analysts plainly believe Health Catalyst is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Health Catalyst has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Summary

Health Catalyst beats Veradigm on 8 of the 14 factors compared between the two stocks.

How does Health Catalyst compare to SOPHiA GENETICS?

Health Catalyst (NASDAQ:HCAT) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Health Catalyst has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Health Catalyst currently has a consensus price target of $2.93, indicating a potential upside of 67.53%. SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 31.23%. Given Health Catalyst's higher probable upside, equities research analysts clearly believe Health Catalyst is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

SOPHiA GENETICS has lower revenue, but higher earnings than Health Catalyst. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
SOPHiA GENETICS	$77.27M	8.27	-$79M	-$1.15	N/A

Health Catalyst has a net margin of -90.61% compared to SOPHiA GENETICS's net margin of -93.86%. Health Catalyst's return on equity of -1.57% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.57%	-0.75%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, SOPHiA GENETICS had 16 more articles in the media than Health Catalyst. MarketBeat recorded 30 mentions for SOPHiA GENETICS and 14 mentions for Health Catalyst. SOPHiA GENETICS's average media sentiment score of 0.07 beat Health Catalyst's score of -0.08 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
SOPHiA GENETICS	9 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Health Catalyst beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to Weave Communications?

Weave Communications (NYSE:WEAV) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Weave Communications has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

In the previous week, Health Catalyst had 11 more articles in the media than Weave Communications. MarketBeat recorded 14 mentions for Health Catalyst and 3 mentions for Weave Communications. Weave Communications' average media sentiment score of 0.57 beat Health Catalyst's score of -0.08 indicating that Weave Communications is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Weave Communications	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Health Catalyst	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

86.8% of Weave Communications shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 16.4% of Weave Communications shares are held by insiders. Comparatively, 19.4% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Weave Communications currently has a consensus target price of $8.33, suggesting a potential upside of 56.44%. Health Catalyst has a consensus target price of $2.93, suggesting a potential upside of 67.53%. Given Health Catalyst's higher possible upside, analysts clearly believe Health Catalyst is more favorable than Weave Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Weave Communications	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Health Catalyst	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23

Weave Communications has higher earnings, but lower revenue than Health Catalyst. Weave Communications is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Weave Communications	$239.02M	1.78	-$28.05M	-$0.25	N/A
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

Weave Communications has a net margin of -7.97% compared to Health Catalyst's net margin of -90.61%. Health Catalyst's return on equity of -1.57% beat Weave Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Weave Communications	-7.97%	-21.37%	-8.44%
Health Catalyst	-90.61%	-1.57%	-0.75%

Summary

Weave Communications and Health Catalyst tied by winning 8 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to Claritev?

Claritev (NYSE:CTEV) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

87.2% of Claritev shares are owned by institutional investors. Comparatively, 85.0% of Health Catalyst shares are owned by institutional investors. 7.4% of Claritev shares are owned by insiders. Comparatively, 19.4% of Health Catalyst shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Claritev has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Claritev has a net margin of -28.46% compared to Health Catalyst's net margin of -90.61%. Claritev's return on equity of 0.00% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-28.46%	N/A	-5.72%
Health Catalyst	-90.61%	-1.57%	-0.75%

In the previous week, Claritev had 10 more articles in the media than Health Catalyst. MarketBeat recorded 24 mentions for Claritev and 14 mentions for Health Catalyst. Claritev's average media sentiment score of 0.41 beat Health Catalyst's score of -0.08 indicating that Claritev is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Claritev	4 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Health Catalyst	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Claritev presently has a consensus target price of $42.83, indicating a potential upside of 2.64%. Health Catalyst has a consensus target price of $2.93, indicating a potential upside of 67.53%. Given Health Catalyst's higher possible upside, analysts clearly believe Health Catalyst is more favorable than Claritev.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Health Catalyst	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23

Health Catalyst has lower revenue, but higher earnings than Claritev. Claritev is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$965.41M	0.74	-$284.28M	-$17.01	N/A
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

Summary

Claritev beats Health Catalyst on 9 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to National Research?

Health Catalyst (NASDAQ:HCAT) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 19.4% of Health Catalyst shares are held by company insiders. Comparatively, 9.2% of National Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

National Research has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
National Research	$137.39M	3.53	$11.60M	$0.25	85.24

Health Catalyst has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, National Research has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

National Research has a net margin of 4.18% compared to Health Catalyst's net margin of -90.61%. National Research's return on equity of 164.26% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.57%	-0.75%
National Research	4.18%	164.26%	14.67%

In the previous week, Health Catalyst had 12 more articles in the media than National Research. MarketBeat recorded 14 mentions for Health Catalyst and 2 mentions for National Research. National Research's average media sentiment score of 1.75 beat Health Catalyst's score of -0.08 indicating that National Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
National Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Health Catalyst currently has a consensus target price of $2.93, indicating a potential upside of 67.53%. National Research has a consensus target price of $26.00, indicating a potential upside of 22.01%. Given Health Catalyst's stronger consensus rating and higher probable upside, analysts plainly believe Health Catalyst is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23
National Research	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Health Catalyst and National Research tied by winning 8 of the 16 factors compared between the two stocks.

Get Health Catalyst News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCAT vs. The Competition

Export

Metric	Health Catalyst	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$134.71M	$1.55B	$7.08B	$12.99B
Dividend Yield	N/A	4.70%	2.58%	10.72%
P/E Ratio	-0.48	24.67	269.68	25.23
Price / Sales	0.42	73.93	601.82	101.15
Price / Cash	0.84	30.32	70.53	50.75
Price / Book	0.50	6.45	13.18	6.24
Net Income	-$177.97M	-$25.90M	$3.45B	$347.70M
7 Day Performance	1.16%	3.73%	0.78%	0.87%
1 Month Performance	-23.58%	5.85%	1.46%	0.90%
1 Year Performance	-40.07%	-15.65%	67.10%	20.13%

Health Catalyst Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCAT Health Catalyst	3.6726 of 5 stars	$1.75 -2.2%	$2.93 +67.5%	-45.7%	$134.71M	$311.14M	N/A	1,200	News Coverage Analyst Forecast Gap Down
MDRX Veradigm	N/A	$4.80 flat	N/A	+6.4%	$587.04M	$1.53B	23.25	8,000	Gap Down
SOPH SOPHiA GENETICS	3.2162 of 5 stars	$6.56 +15.2%	$9.00 +37.3%	+145.0%	$552.42M	$77.27M	N/A	520	High Trading Volume
WEAV Weave Communications	2.6191 of 5 stars	$6.82 +1.0%	$8.33 +22.3%	-33.9%	$542.27M	$239.02M	N/A	890
CTEV Claritev	2.1611 of 5 stars	$26.27 +8.2%	$34.50 +31.3%	-36.5%	$447.90M	$965.41M	N/A	3,000	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCAT) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Catalyst (HCAT) Competitors

HCAT vs. MDRX, SOPH, WEAV, CTEV, and NRC

How does Health Catalyst compare to Veradigm?

Summary

How does Health Catalyst compare to SOPHiA GENETICS?

Summary

How does Health Catalyst compare to Weave Communications?

Summary

How does Health Catalyst compare to Claritev?

Summary

How does Health Catalyst compare to National Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAT vs. The Competition

Health Catalyst Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Catalyst (HCAT) Competitors

HCAT vs. MDRX, SOPH, WEAV, CTEV, and NRC

How does Health Catalyst compare to Veradigm?

Do institutionals & insiders have more ownership in HCAT or MDRX?

Is HCAT or MDRX more profitable?

Which has higher valuation & earnings, HCAT or MDRX?

Does the media prefer HCAT or MDRX?

Do analysts prefer HCAT or MDRX?

Which has more risk and volatility, HCAT or MDRX?

Summary

How does Health Catalyst compare to SOPHiA GENETICS?

Which has more risk & volatility, HCAT or SOPH?

Do analysts rate HCAT or SOPH?

Which has stronger earnings and valuation, HCAT or SOPH?

Is HCAT or SOPH more profitable?

Do insiders & institutionals have more ownership in HCAT or SOPH?

Does the media prefer HCAT or SOPH?

Summary

How does Health Catalyst compare to Weave Communications?

Which has more volatility and risk, WEAV or HCAT?

Does the media favor WEAV or HCAT?

Do insiders and institutionals have more ownership in WEAV or HCAT?

Do analysts recommend WEAV or HCAT?

Which has better earnings and valuation, WEAV or HCAT?

Is WEAV or HCAT more profitable?

Summary

How does Health Catalyst compare to Claritev?

Do insiders & institutionals believe in CTEV or HCAT?

Which has more volatility & risk, CTEV or HCAT?

Is CTEV or HCAT more profitable?

Does the media favor CTEV or HCAT?

Do analysts recommend CTEV or HCAT?

Which has preferable earnings and valuation, CTEV or HCAT?

Summary

How does Health Catalyst compare to National Research?

Do institutionals & insiders have more ownership in HCAT or NRC?

Which has preferable valuation & earnings, HCAT or NRC?

Which has more volatility and risk, HCAT or NRC?

Is HCAT or NRC more profitable?

Does the media prefer HCAT or NRC?

Do analysts prefer HCAT or NRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAT vs. The Competition

Health Catalyst Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools